AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Study to Investigate Daily Symptom Variability, Symptom Effects on Morning Activities of Chronic Obstructive Disease
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- First Posted Date
- 2010-04-26
- Last Posted Date
- 2011-01-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 515
- Registration Number
- NCT01110564
- Locations
- 🇹🇷
Research Site, Yozgat, Turkey
A Drug-drug Interaction Study to Investigate the Effects of AZD1981 on the Metabolism and Pharmacodynamics of Oral Contraceptives
Phase 1
Completed
- Conditions
- Oral Contraceptives
- Interventions
- First Posted Date
- 2010-04-26
- Last Posted Date
- 2010-11-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 28
- Registration Number
- NCT01110525
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
- First Posted Date
- 2010-04-21
- Last Posted Date
- 2014-07-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 18206
- Registration Number
- NCT01107886
- Locations
- 🇬🇧
Research Site, Whitstable, United Kingdom
A Non-interventional Survey on the EGFR (Epidermal Growth Factor Receptor) Mutation Status in Completely Resected Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Adenocarcinoma Histology
Completed
- Conditions
- Non-Small Cell Lung Cancer
- First Posted Date
- 2010-04-20
- Last Posted Date
- 2014-03-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 591
- Registration Number
- NCT01106781
- Locations
- 🇨🇳
Research Site, Hangzhou, Zhejiang, China
Evaluation of Compliance With Management of Acute Coronary Syndrome on Discharge From Cardiac Intensive Care
Terminated
- Conditions
- Acute Coronary Syndrome
- First Posted Date
- 2010-04-16
- Last Posted Date
- 2010-10-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1000
- Registration Number
- NCT01105325
- Locations
- 🇫🇷
Research Site, Villeneuve St Georges Cedex, France
A Study to Examine the Efficacy, Safety and Tolerability, and Pharmacokinetics of Exenatide Once Monthly Suspension
Phase 2
Completed
- Conditions
- Type 2 Diabetes
- Interventions
- First Posted Date
- 2010-04-15
- Last Posted Date
- 2015-08-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 121
- Registration Number
- NCT01104701
- Locations
- 🇺🇸
Research Site, Lincoln, Nebraska, United States
Non-interventional Study to Evaluate the Change in Symptoms Scores and Treatment Response After 4 Weeks of Proton-Pump Inhibitors (PPI) Treatment
Completed
- Conditions
- Gastroesophageal Reflux
- First Posted Date
- 2010-04-15
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 952
- Registration Number
- NCT01103804
- Locations
- 🇷🇴
Research Site, Vanatori(GL), Romania
Observations From Long Term Responders in the Gefitinib (Iressa) Expanded Access Program (EAP)
Completed
- Conditions
- Non-Small Cell Lung Cancer
- First Posted Date
- 2010-04-14
- Last Posted Date
- 2011-10-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 10
- Registration Number
- NCT01103089
- Locations
- 🇳🇱
Research Site, Zutphen, Netherlands
Investigate the Effect of AZD1656 on the Pharmacokinetics of Digoxin in Type 2 Diabetes Mellitus Patients
Phase 1
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2010-04-14
- Last Posted Date
- 2011-01-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 20
- Registration Number
- NCT01103622
- Locations
- 🇺🇸
Research Site, Chula Vista, California, United States
Investigate the Effect of AZD1656 on the Pharmacokinetics and Pharmacodynamics of Warfarin in Type 2 Diabetes Mellitus (T2DM) Patients
Phase 1
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2010-04-14
- Last Posted Date
- 2010-11-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 16
- Registration Number
- NCT01103609
- Locations
- 🇬🇧
Research Site, London, United Kingdom